Spira, A. I., Drilon, A. E., Goldman, J. W., Florez, N., Christopoulos, P., Pérol, M., Chen, D., Ran, F., Zhang, X., Liu, G., Zhou, C. (2026). Randomized, double-blind, phase 3 TRUST-IV study of adjuvant taletrectinib vs placebo in patients with stage IB–IIIA ROS1+ non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps8130